CN100335046C - 组合物 - Google Patents
组合物 Download PDFInfo
- Publication number
- CN100335046C CN100335046C CNB018084036A CN01808403A CN100335046C CN 100335046 C CN100335046 C CN 100335046C CN B018084036 A CNB018084036 A CN B018084036A CN 01808403 A CN01808403 A CN 01808403A CN 100335046 C CN100335046 C CN 100335046C
- Authority
- CN
- China
- Prior art keywords
- acetaminophen
- weight
- minutes
- compositions
- mutually
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims description 44
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims abstract description 205
- 229960005489 paracetamol Drugs 0.000 claims abstract description 94
- 238000004090 dissolution Methods 0.000 claims abstract description 19
- 238000000338 in vitro Methods 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 229920000642 polymer Polymers 0.000 claims description 12
- 239000000758 substrate Substances 0.000 claims description 11
- -1 hydroxypropyl Chemical group 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229920003169 water-soluble polymer Polymers 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 229920003176 water-insoluble polymer Polymers 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- ADVGKWPZRIDURE-UHFFFAOYSA-N 2'-Hydroxyacetanilide Chemical class CC(=O)NC1=CC=CC=C1O ADVGKWPZRIDURE-UHFFFAOYSA-N 0.000 claims 1
- 238000013268 sustained release Methods 0.000 abstract description 8
- 239000012730 sustained-release form Substances 0.000 abstract description 8
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract description 4
- 239000003826 tablet Substances 0.000 description 61
- 208000002193 Pain Diseases 0.000 description 34
- 230000036407 pain Effects 0.000 description 30
- 239000003814 drug Substances 0.000 description 29
- 238000002360 preparation method Methods 0.000 description 26
- 239000007939 sustained release tablet Substances 0.000 description 19
- 238000009472 formulation Methods 0.000 description 13
- 238000002156 mixing Methods 0.000 description 12
- 238000011160 research Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 230000036470 plasma concentration Effects 0.000 description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 239000002775 capsule Substances 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 229920000881 Modified starch Polymers 0.000 description 4
- 208000029618 autoimmune pulmonary alveolar proteinosis Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000007907 direct compression Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000010355 oscillation Effects 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229940072651 tylenol Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- 208000000094 Chronic Pain Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000007948 fast release tablet Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 208000003870 Drug Overdose Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 206010033296 Overdoses Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 231100000725 drug overdose Toxicity 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012154 short term therapy Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000004357 third molar Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Confectionery (AREA)
Abstract
Description
成分 | 片剂A | 片剂B | ||
缓释层 | mg/片 | 重量% | mg/片 | 重量% |
对乙酰氨基酚 | 264.08 | 34.75 | 403.39 | 52.10 |
高粘度HPMC | 18.96 | 2.49 | 28.96 | 3.74 |
预胶凝化淀粉 | 21.05 | 2.77 | 32.15 | 4.15 |
聚乙烯吡咯烷酮 | 5.88 | 0.77 | 8.98 | 1.16 |
低粘度HPMC | 5.09 | 0.67 | 7.77 | 1.00 |
硬脂酸镁 | 0.95 | 0.12 | 1.45 | 0.19 |
速释层 | ||||
可直接压片的对乙酰氨基酚颗粒DC90# | 436.00 | 57.36 | 283.5 | 36.62 |
DC90中的对乙酰氨基酚含量 | (389.80) | (51.28) | (260.00) | (33.58) |
薄膜及蜡包衣 | 8.05 | 1.06 | 8.05 | 1.04 |
总量 | 760.05 | 100.000 | 774.25 | 100.00 |
SR∶IR APAP重量% | 41.1∶59.9 | 60.5∶39.5 |
时间(分钟) | 对乙酰氨基酚释放百分比 | |
缓释650mg对乙酰氨基酚样片A | 缓释650mg对乙酰氨基酚样片B | |
15分钟 | 51.3 | 39.1 |
60分钟 | 71.2 | 54.7 |
120分钟 | 87.0 | 68.7 |
180分钟 | 99.3 | 79.4 |
240分钟 | 103.7 | 89.4 |
300分钟 | 96.0 | |
360分钟 | 97.3 |
成分 | 片剂C | |
缓释层 | mg/片 | 重量百分比 |
对乙酰氨基酚 | 473.57 | 64.39 |
高粘度HPMC | 15.43 | 2.10 |
预胶凝化淀粉 | 5.14 | 0.70 |
聚乙烯吡咯烷酮 | 10.28 | 1.40 |
低粘度HPMC | 8.23 | 1.12 |
硬脂酸镁 | 1.54 | 0.21 |
速释层 | ||
可直接压片的对乙酰氨基酚颗粒DC90 | 214.92 | 29.22 |
(DC90中的对乙酰氨基酚含量) | (193.43) | (26.30) |
薄膜和蜡包衣 | 6.305 | 0.86 |
总量 | 735.42 | 100.00 |
SR∶IR APAP重量% | 71∶29 |
时间(分钟) | 体外释放结果(对乙酰氨基酚释放百分数) |
1560120180 | 39.4%64.4%89.0%101.8% |
时间(分钟) | 体外释放结果(对乙酰氨基酚释放百分数) |
1560120180 | 40.8%65.0%90.2%101.8% |
Claims (11)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0009522.4 | 2000-04-19 | ||
GBGB0009522.4A GB0009522D0 (en) | 2000-04-19 | 2000-04-19 | Composition |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1426298A CN1426298A (zh) | 2003-06-25 |
CN100335046C true CN100335046C (zh) | 2007-09-05 |
Family
ID=9890126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB018084036A Expired - Lifetime CN100335046C (zh) | 2000-04-19 | 2001-04-12 | 组合物 |
Country Status (25)
Country | Link |
---|---|
US (2) | US7943170B2 (zh) |
EP (1) | EP1274402B1 (zh) |
JP (1) | JP2003531165A (zh) |
KR (1) | KR100845660B1 (zh) |
CN (1) | CN100335046C (zh) |
AT (1) | ATE438388T1 (zh) |
AU (2) | AU2001260212C1 (zh) |
BR (1) | BR0110129A (zh) |
CA (1) | CA2406373C (zh) |
CO (1) | CO5280073A1 (zh) |
CY (1) | CY1109483T1 (zh) |
CZ (1) | CZ303275B6 (zh) |
DE (1) | DE60139462D1 (zh) |
DK (1) | DK1274402T3 (zh) |
EA (1) | EA006103B1 (zh) |
ES (1) | ES2329971T3 (zh) |
GB (1) | GB0009522D0 (zh) |
HK (1) | HK1053601A1 (zh) |
HU (1) | HU230033B1 (zh) |
MX (1) | MXPA02010347A (zh) |
NZ (1) | NZ521799A (zh) |
TW (1) | TWI282286B (zh) |
UA (1) | UA76417C2 (zh) |
WO (1) | WO2001080834A1 (zh) |
ZA (1) | ZA200208084B (zh) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0009522D0 (en) * | 2000-04-19 | 2000-06-07 | Smithkline Beecham Plc | Composition |
TWI319713B (en) | 2002-10-25 | 2010-01-21 | Sustained-release tramadol formulations with 24-hour efficacy | |
US8487002B2 (en) | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
US20040186180A1 (en) * | 2003-03-21 | 2004-09-23 | Gelotte Cathy K. | Non-steroidal anti-inflammatory drug dosing regimen |
CN100348974C (zh) * | 2003-09-30 | 2007-11-14 | 北京东方凯恩医药科技有限公司 | 一种药物组合物的检测方法 |
US20050095299A1 (en) * | 2003-10-30 | 2005-05-05 | Wynn David W. | Controlled release analgesic suspensions |
JP5269595B2 (ja) | 2005-09-09 | 2013-08-21 | アンジェリーニ ラボファーム リミテッド ライアビリティ カンパニー | 1日1回投与用トラゾドン組成物 |
US20080057122A1 (en) * | 2006-08-31 | 2008-03-06 | Aaipharma Inc. | Acetaminophen pharmaceutical compositions |
ES2541809T3 (es) * | 2007-10-16 | 2015-07-24 | Paladin Labs Inc. | Composición bicapa para la liberación sostenida de acetaminofeno y tramadol |
EP2219612A4 (en) | 2007-12-17 | 2013-10-30 | Paladin Labs Inc | CONTROLLED RELEASE FORMULATION AVOIDING IMPROPER USES |
US9226907B2 (en) | 2008-02-01 | 2016-01-05 | Abbvie Inc. | Extended release hydrocodone acetaminophen and related methods and uses thereof |
US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
EP2262484B1 (en) | 2008-03-11 | 2013-01-23 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
EP2367541B1 (en) | 2008-12-16 | 2014-07-16 | Paladin Labs Inc. | Misuse preventative, controlled release formulation |
CA2752233C (en) * | 2009-02-13 | 2017-01-03 | Romark Laboratories L.C. | Controlled release pharmaceutical formulations of nitazoxanide |
US20110052685A1 (en) * | 2009-08-31 | 2011-03-03 | Depomed, Inc. | Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen |
US8597681B2 (en) | 2009-12-22 | 2013-12-03 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
SG194605A1 (en) * | 2011-05-06 | 2013-12-30 | Glaxosmithkline Llc | Sustained release paracetamol formulations |
US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
US8658631B1 (en) | 2011-05-17 | 2014-02-25 | Mallinckrodt Llc | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia |
US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
US20140206740A1 (en) * | 2011-07-30 | 2014-07-24 | Neurovance, Inc. | Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters |
EA028481B1 (ru) * | 2012-10-18 | 2017-11-30 | Эббви Инк. | Препараты производных пиримидиндиона |
WO2016042570A1 (en) * | 2014-09-16 | 2016-03-24 | Suresh Pareek | Extended release formulation of acetaminophen |
ES2884973T3 (es) | 2016-03-09 | 2021-12-13 | Nls Pharmaceutics Ag | Comprimido multicapa de mazindol de IR/SR y su utilización para el tratamiento del trastorno por déficit de atención/hiperactividad (ADHD) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0305051A1 (en) * | 1987-07-27 | 1989-03-01 | McNeilab, Inc. | Orally sustained-release acetaminophen formulation and process to obtain it |
WO2000013673A1 (en) * | 1998-09-03 | 2000-03-16 | Ascent Pediatrics Inc | Extended release acetaminophen |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2058562B (en) * | 1979-09-14 | 1983-11-30 | Beecham Group Ltd | Pharmaceutical compositions containing paracetamol and ascorbic acid |
US4786503A (en) * | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
EP0418596A3 (en) * | 1989-09-21 | 1991-10-23 | American Cyanamid Company | Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form |
US5009895A (en) * | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
US5900425A (en) * | 1995-05-02 | 1999-05-04 | Bayer Aktiengesellschaft | Pharmaceutical preparations having controlled release of active compound and processes for their preparation |
US5773031A (en) * | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
BE1011045A3 (fr) * | 1997-03-14 | 1999-04-06 | Ucb Sa | Compositions pharmaceutiques pour la liberation controlee de substances actives. |
FR2766708B1 (fr) | 1997-07-30 | 2000-05-05 | Galenix Dev | Composition contenant de l'hydroxypropylcellulose, de l'hydroxypropylmethylcellulose et/ou de l'ethylcellullose a titre d'agents desintegrants, et procede d'obtention |
US5945123A (en) * | 1998-04-02 | 1999-08-31 | K-V Pharmaceutical Company | Maximizing effectiveness of substances used to improve health and well being |
US6254891B1 (en) | 1998-09-03 | 2001-07-03 | Ascent Pediatrics, Inc. | Extended release acetaminophen |
GB0009522D0 (en) * | 2000-04-19 | 2000-06-07 | Smithkline Beecham Plc | Composition |
US7897172B2 (en) * | 2004-05-18 | 2011-03-01 | L. Perrigo Company | Tablets exhibiting reduced drug release variability |
-
2000
- 2000-04-19 GB GBGB0009522.4A patent/GB0009522D0/en not_active Ceased
-
2001
- 2001-04-12 AT AT01933832T patent/ATE438388T1/de not_active IP Right Cessation
- 2001-04-12 AU AU2001260212A patent/AU2001260212C1/en not_active Expired
- 2001-04-12 JP JP2001577934A patent/JP2003531165A/ja active Pending
- 2001-04-12 DE DE60139462T patent/DE60139462D1/de not_active Expired - Lifetime
- 2001-04-12 MX MXPA02010347A patent/MXPA02010347A/es active IP Right Grant
- 2001-04-12 ES ES01933832T patent/ES2329971T3/es not_active Expired - Lifetime
- 2001-04-12 HU HU0300698A patent/HU230033B1/hu not_active IP Right Cessation
- 2001-04-12 CZ CZ20023470A patent/CZ303275B6/cs not_active IP Right Cessation
- 2001-04-12 CA CA2406373A patent/CA2406373C/en not_active Expired - Fee Related
- 2001-04-12 EA EA200200954A patent/EA006103B1/ru not_active IP Right Cessation
- 2001-04-12 CN CNB018084036A patent/CN100335046C/zh not_active Expired - Lifetime
- 2001-04-12 KR KR1020027014009A patent/KR100845660B1/ko active IP Right Grant
- 2001-04-12 EP EP01933832A patent/EP1274402B1/en not_active Expired - Lifetime
- 2001-04-12 BR BR0110129-3A patent/BR0110129A/pt active Search and Examination
- 2001-04-12 US US10/257,077 patent/US7943170B2/en not_active Expired - Fee Related
- 2001-04-12 NZ NZ521799A patent/NZ521799A/xx not_active IP Right Cessation
- 2001-04-12 AU AU6021201A patent/AU6021201A/xx active Pending
- 2001-04-12 DK DK01933832T patent/DK1274402T3/da active
- 2001-04-12 WO PCT/EP2001/004302 patent/WO2001080834A1/en active IP Right Grant
- 2001-04-17 CO CO01029583A patent/CO5280073A1/es not_active Application Discontinuation
- 2001-04-18 TW TW090109284A patent/TWI282286B/zh not_active IP Right Cessation
- 2001-12-04 UA UA2002108076A patent/UA76417C2/uk unknown
-
2002
- 2002-10-08 ZA ZA200208084A patent/ZA200208084B/en unknown
-
2003
- 2003-06-16 HK HK03104302.2A patent/HK1053601A1/xx not_active IP Right Cessation
-
2009
- 2009-10-13 CY CY20091101055T patent/CY1109483T1/el unknown
-
2011
- 2011-03-29 US US13/074,944 patent/US20110177168A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0305051A1 (en) * | 1987-07-27 | 1989-03-01 | McNeilab, Inc. | Orally sustained-release acetaminophen formulation and process to obtain it |
US4820522A (en) * | 1987-07-27 | 1989-04-11 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
WO2000013673A1 (en) * | 1998-09-03 | 2000-03-16 | Ascent Pediatrics Inc | Extended release acetaminophen |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100335046C (zh) | 组合物 | |
CN1101187C (zh) | 氟西汀药物制剂 | |
TWI466690B (zh) | 塗膜錠劑調配物 | |
CN1168440C (zh) | 左旋多巴/卡比多巴/恩他卡朋药物制剂 | |
JP4771565B2 (ja) | 持続放出性製剤 | |
EP3287124B1 (en) | Oral dosage form of ketamine | |
CN1109328A (zh) | 24小时释放甲氧乙心安的持续释放制剂 | |
AU2001260212A1 (en) | Composition | |
CN1328460A (zh) | 药物组合制剂 | |
CN1946426A (zh) | 用于口服施用HMG-CoA还原酶抑制剂的持续释放制剂和其制备方法 | |
CN1253497A (zh) | 含扑热息痛的吞咽片剂 | |
WO2006115770A2 (en) | Orally disintegrating pharmaceutical tablet formulations of olanzapine | |
CN1538837A (zh) | 含有对乙酰氨基酚的吞咽片 | |
CN103648486A (zh) | 缓释对乙酰氨基酚制剂 | |
CN1248693C (zh) | 复方氨基葡萄糖盐缓释制剂及其制备方法 | |
CN1188113C (zh) | 含有profen和其它活性化合物的组合的药物混合物 | |
JP4696210B2 (ja) | イソソルビド‐5‐モノニトレートを有効成分とする徐放性錠剤及びその製造方法 | |
CN1389208A (zh) | 苯二氮卓类药物口服脉冲释药系统及其制备方法 | |
CN1684666A (zh) | 制备莫达非尼口服剂型的方法 | |
CN1593413A (zh) | 一种复方缓释胶囊及其制备方法 | |
CN108785273B (zh) | 一种恩替卡韦胶囊药物组合物及其制备方法 | |
CN1049114C (zh) | 一种制备缓释药物制剂的方法 | |
CN105636580A (zh) | 包含1-[6-(吗啉-4-基)嘧啶-4-基]-4-(1h-1,2,3-三唑-1-基)-1h-吡唑-5-醇钠的药物剂型 | |
JP2012520892A (ja) | アリスキレンを含む医薬組成物 | |
CN1638752A (zh) | 药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: GLAXOSMITHKLINE DENGJIAWEN CO., LTD. Free format text: FORMER OWNER: SMITHKLINE BEECHAM CORPORATION Effective date: 20140930 Owner name: GLAXOSMITHKLINE CONSUMER HEALTHCARE INVESTMENT CO. Free format text: FORMER OWNER: GLAXOSMITHKLINE DENGJIAWEN CO., LTD. Effective date: 20140930 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: GLAXOSMITHKLINE CONSUMER HEALTHCARE INVESTMENT COM Free format text: FORMER NAME: GLAXOSMITHKLINE CONSUMER HEALTHCARE INVESTMENT CO., LTD. (IRELAND) NO. 2 Owner name: SMITHKLINE BEECHAM CORPORATION Free format text: FORMER NAME: SMITHKLINE BEECHAM PLC |
|
CP01 | Change in the name or title of a patent holder |
Address after: Ireland Waterford Patentee after: GlaxoSmithKline consumer health investment company (Ireland) No. two Address before: Ireland Waterford Patentee before: GlaxoSmithKline consumer health Investments Ltd. (Ireland) No two Address after: England Patentee after: Smith Klein Beecham LLC Address before: England Patentee before: Smithkline Beecham PLC |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140930 Address after: Ireland Waterford Patentee after: GlaxoSmithKline consumer health Investments Ltd. (Ireland) No two Address before: Ireland Waterford Patentee before: GlaxoSmithKline Deng Gavin LLC Effective date of registration: 20140930 Address after: Ireland Waterford Patentee after: GlaxoSmithKline Deng Gavin LLC Address before: England Patentee before: Smith Klein Beecham LLC |
|
CX01 | Expiry of patent term |
Granted publication date: 20070905 |
|
CX01 | Expiry of patent term |